title: Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens.
abstract: Tumor cells that survive radiation are more sensitive to T-cell-mediated lysis due to a spectrum of biological adaptations to cellular stress (defined as immunogenic modulation), including enhanced antigen processing and cell-surface presence of calreticulin. This mechanism can be exploited to maximize clinical benefit in patients receiving radiotherapy plus immunotherapy.
authors.affiliation: Recombinant Vaccine Group; Laboratory of Tumor Immunology and Biology; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda, MD USA.
authors.forename: Sofia R
authors.initials: SR
authors.lastname: Gameiro
authors.affiliation: Recombinant Vaccine Group; Laboratory of Tumor Immunology and Biology; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda, MD USA.
authors.forename: Andressa
authors.initials: A
authors.lastname: Ardiani
authors.affiliation: Recombinant Vaccine Group; Laboratory of Tumor Immunology and Biology; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda, MD USA.
authors.forename: Anna
authors.initials: A
authors.lastname: Kwilas
authors.affiliation: Recombinant Vaccine Group; Laboratory of Tumor Immunology and Biology; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda, MD USA.
authors.forename: James W
authors.initials: JW
authors.lastname: Hodge
keywords: CTL-mediated lysis; ER-stress; antigen-processing machinery; calreticulin; immunogenic modulation; immunotherapy; radiation therapy; therapeutic cancer vaccine
references.citation: Oncoimmunology. 2013 Dec 1;2(12):e26937
references.pmid: 24498561
references.citation: Br J Cancer. 2014 Mar 18;110(6):1472-80
references.pmid: 24556625
references.citation: Annu Rev Immunol. 2013;31:51-72
references.pmid: 23157435
references.citation: Front Oncol. 2012 Sep 06;2:104
references.pmid: 22973551
references.citation: Mol Cancer Res. 2013 Jan;11(1):5-12
references.pmid: 23175523
references.citation: N Engl J Med. 2012 Mar 22;366(12):1156-8
references.pmid: 22435376
references.citation: Oncotarget. 2014 Jan 30;5(2):403-16
references.pmid: 24480782
references.citation: J Clin Invest. 2014 Feb;124(2):687-95
references.pmid: 24382348
references.citation: J Natl Cancer Inst. 2013 Feb 20;105(4):256-65
references.pmid: 23291374